Patents

New adenoviral vector technology wins patent; Introgen gets license

Published in Gene Therapy Weekly, January 15th, 2004

Introgen Therapeutics (INGN) announced that a patent directed to classes of adenoviral vectors has been awarded to the board of regents of the University of Texas System and is exclusively licensed to Introgen.

These classes of adenoviral vectors are particularly important in the commercial production of adenovirus vectors, and in a number of emerging cancer and gene therapy fields, such as the use of oncolytic viruses to kill cancer cells. The patent claims of U.S. 6,630,344 broadly cover adenoviruses engineered to control tissue replication through the use of tissue-specific control elements.

Dr. David L. Parker, Introgen's vice president for...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2004-01-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry